Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $19.64

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $19.6364.

A number of research firms recently issued reports on BCRX. Weiss Ratings upgraded shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Evercore began coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Royal Bank Of Canada lowered their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, January 30th.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the sale, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. RFG Advisory LLC purchased a new stake in BioCryst Pharmaceuticals during the first quarter worth approximately $27,329,000. OP Asset Management Ltd purchased a new stake in BioCryst Pharmaceuticals during the first quarter worth approximately $11,927,000. Rockefeller Capital Management L.P. grew its stake in BioCryst Pharmaceuticals by 403.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 26,797 shares of the biotechnology company’s stock worth $209,000 after buying an additional 21,472 shares during the period. Invesco Ltd. grew its stake in BioCryst Pharmaceuticals by 40.8% during the fourth quarter. Invesco Ltd. now owns 1,354,897 shares of the biotechnology company’s stock worth $10,568,000 after buying an additional 392,521 shares during the period. Finally, Mackenzie Financial Corp grew its stake in BioCryst Pharmaceuticals by 16.6% during the fourth quarter. Mackenzie Financial Corp now owns 150,728 shares of the biotechnology company’s stock worth $1,152,000 after buying an additional 21,411 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $9.19 on Friday. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.31. The firm has a 50 day moving average price of $8.68 and a 200 day moving average price of $7.68. The company has a market cap of $2.30 billion, a price-to-earnings ratio of 7.66 and a beta of 0.70.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The firm had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. During the same period in the previous year, the firm earned ($0.13) earnings per share. BioCryst Pharmaceuticals’s revenue was up 209.1% compared to the same quarter last year. Sell-side analysts predict that BioCryst Pharmaceuticals will post 0.27 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.